Company

Aurinia Pharmaceuticals Inc.

Headquarters: Victoria, BC, Canada

Employees: 294

CEO: Mr. Peter S. Greenleaf M.B.A.

TSX: AUP -2.71%

Market Cap

C$2.15 Billion

CAD as of July 1, 2021

US$1.74 Billion

Market Cap History

Aurinia Pharmaceuticals Inc. market capitalization over time

Evolution of Aurinia Pharmaceuticals Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Aurinia Pharmaceuticals Inc.

Detailed Description

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Aurinia Pharmaceuticals Inc. has the following listings and related stock indices.


Stock: TSX: AUP wb_incandescent

Stock: NASDAQ: AUPH wb_incandescent

Stock: FSX: IKAP wb_incandescent

Details

Headquarters:

4464 Markham Street

Suite 1203

Victoria, BC V8Z 7X8

Canada

Phone: 250 744 2487

Fax: 250 744 2498